During the corresponding time, Quoin Pharmaceuticals Ltd saw a revenue deteriorated by -73.6 % year on year, sequentially revenue fell by -88.08 %. While revenue at the Quoin Pharmaceuticals Ltd 's corporate clients
Quoin Pharmaceuticals Ltd's Comment on Sales, Marketing and Customers
The company plans to commercialize QRX003 for the treatment of Netherton Syndrome (NS) in the U.S., Western Europe, and Japan through its own commercial infrastructure and partnerships. It intends to self-commercialize QRX003 and other rare disease products in these regions, including establishing a Japanese subsidiary. The target market comprises patients and caregivers, with treatment typically administered by a limited number of board-certified dermatologists in major urban centers. Outside these territories, the company maintains nine marketing partnerships covering 61 countries, including Australia, New Zealand, the Middle East, Central and Eastern Europe, Turkey, Canada, China, Taiwan, Hong Kong, Singapore, and key countries in Latin America. Physicians treating NS patients often also treat related disorders such as Peeling Skin Syndrome, SAM Syndrome, and other Ichthyosis-related disorders, enabling sales personnel to address multiple products. The company seeks to expand its product portfolio through in-licensing, acquisitions, or research partnerships, potentially extending beyond rare skin diseases. Pricing for QRX003 has not been finalized and may depend on FDA labeling, pharmacoeconomic data, and government contracts. The market is competitive, with other biotechnology and pharmaceutical companies, academic institutions, and research organizations developing treatments for substance use and related conditions.
ASHBURN, Va. December 18, 2024 In a groundbreaking development for the treatment of rare genetic diseases, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company, has announced positive interim data from two ongoing clinical studies involving Netherton syndrome (NS), a rare inherited genetic disorder. This announcement comes on the heels of Quoin’s prior declaration that it initiated clinical testing of its lead product, QRX003, in a pediatric patient diagnosed with Netherton Syndrome.Netherton Syndrome is a severe skin condition characterized by a triad of symptoms: congenital ichthyosis, hair shaft abnormalities, and a predisposition to allergic diseases, all of...
Peeling Skin Syndrome (PSS) represents a rare group of autosomal diseases characterized by the shedding of the outermost layer of skin, leading to significant morbidity and psychosocial challenges for affected individuals. With no approved treatments or cures available, PSS poses a significant gap in dermatological care, demanding urgent attention from the research community. Quoin Pharmaceuticals has announced the initiation of a clinical study aimed at exploring potential therapeutic avenues for this debilitating condition. This article delves into the implications of this clinical study, the pathophysiology of Peeling Skin Syndrome, and the impact this research could have on patients and families grappli...
Quoin Pharmaceuticals Ltd’s Comment on Sales, Marketing and Customers
The company plans to commercialize QRX003 for the treatment of Netherton Syndrome (NS) in the U.S., Western Europe, and Japan through its own commercial infrastructure and partnerships. It intends to self-commercialize QRX003 and other rare disease products in these regions, including establishing a Japanese subsidiary. The target market comprises patients and caregivers, with treatment typically administered by a limited number of board-certified dermatologists in major urban centers. Outside these territories, the company maintains nine marketing partnerships covering 61 countries, including Australia, New Zealand, the Middle East, Central and Eastern Europe, Turkey, Canada, China, Taiwan, Hong Kong, Singapore, and key countries in Latin America. Physicians treating NS patients often also treat related disorders such as Peeling Skin Syndrome, SAM Syndrome, and other Ichthyosis-related disorders, enabling sales personnel to address multiple products. The company seeks to expand its product portfolio through in-licensing, acquisitions, or research partnerships, potentially extending beyond rare skin diseases. Pricing for QRX003 has not been finalized and may depend on FDA labeling, pharmacoeconomic data, and government contracts. The market is competitive, with other biotechnology and pharmaceutical companies, academic institutions, and research organizations developing treatments for substance use and related conditions.
Sources:
Quoin Pharmaceuticals Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Quoin Pharmaceuticals Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Quoin Pharmaceuticals Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
